XNAS
ACB
Market cap277mUSD
Oct 08, Last price
4.43USD
1D
-0.67%
1Q
63.47%
Jan 2017
-97.85%
IPO
-95.91%
Name
Aurora Cannabis Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aurora Cannabis Inc., based in Edmonton, Canada, is a global enterprise focused on the cultivation, distribution, and sale of cannabis and cannabis-derived goods. Within Canada, the company provides both medical and recreational cannabis products. Its international operations include supplying wholesale medical cannabis to various regions, such as the European Union, Australia, the Caribbean, South America, and Israel. Additionally, Aurora distributes and sells hemp-derived cannabidiol (CBD) products within the United States market. The company's product offerings are extensive, featuring dried cannabis, cannabis oils, capsules, edible cannabis, and concentrated extracts. These products can be consumed through various methods, including smoking, vaporizing, or ingestion in oil, capsule, edible, or extract forms. Aurora also offers dried milled strains and specific cannabis oil formulations, alongside patient counseling and outreach services. Its adult-use brand collection features names like Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, while its CBD offerings include Reliva and KG7. For medical cannabis patients, the company provides brands such as MedReleaf, CanniMed, Aurora, and WMMC.
Key people
Glen Ibbott
Chief Financial Officer · since 2017
Thomas Larssen
President of Aurora Larssen Projects Ltd · since 2017
Chief Operational Officer · since 2017
Debra Wilson
Chief Human Resource Officer · since 2018
Andre Jerome
Senior Vice President - Business Integration · since 2018
Shane Morris
Senior Vice President - Product Development and Regulatory Affairs · since 2018
Rick Savone
Senior Vice President - Global Government Relations · since 2019
Darryl Andrew Vleeming
Chief Information Officer · since 2017
Darren Anthony Karasiuk
Chief Commercial Officer · since 2019
Jonathan Page
Chief Science Officer · since 2018
Jillian L. Swainson
Chief Legal Officer, Corporate Secretary · since 2019
Neil Belot
Director · since 2017
President, Director · since 2014
Independent Director · since 2019
Norma Beauchamp
Independent Director · since 2018
Independent Director · since 2020
Jason R.B. Dyck
Director · since 2015
Lance Friedmann
Independent Director · since 2020
Ronald Funk
Lead Independent Director · since 2019
Independent Director · since 2015
Headquarters & legal address
510 Seymour Street
Suite 900
Vancouver, BC V6B 3J5
CA
Suite 900
Vancouver, BC V6B 3J5
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||